Conference Correspondent

Nivolumab and Erlotinib in EGFR-Mutation Positive Treatment-Resistant Advanced NSCLC

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 2, 2014

Nivolumab in Chemotherapy-Naïve Advanced NSCLC

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 2, 2014

Blinatumomab in Relapsed/Refractory Acute Lymphoblastic Leukemia

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 2, 2014

Adoptive T-Cell Therapy for Cervical Cancer

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 2, 2014

Pembrolizumab (MK-3745) in Metastatic Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 2, 2014

Concurrent Treatment of Advanced Melanoma with Ipilimumab and Nivolumab

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 2, 2014

Ipilimumab for Initial Treatment of Metastatic Uveal Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 2, 2014

Nivolumab Combined with Ipilimumab in Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 2, 2014

Gefitinib Plus Carboplatin/Pemetrexed as First-Line Therapy of EGFR+ NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent — June 2, 2014

First-Line Nivolumab Monotherapy in Advanced NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent — June 2, 2014

Page 39 of 44

36
37
38
39
40
41
42